Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer

By Buonerba Carlo   Pond Gregory R   Sonpavde Guru   Federico Piera   Rescigno Pasquale   Puglia Livio   Bosso Davide   Virtuoso Antonella   Policastro Tania   Izzo Michela   Vaccaro Luca   Ferro Matteo   Aieta Michele   Perdonà Sisto   Palmieri Giovannella   De Placido Sabino   Di Lorenzo Giuseppe  

Future Oncology, Vol. 9, Iss. 6, 2013-06 ,pp. : 889-897

Future Medicine

Access to resources Recommend Favorite

Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?

By Aragon-Ching Jeanny B  

Future Oncology, Vol. 9, Iss. 5, 2013-05 ,pp. : 619-622

Future Medicine

Access to resources Recommend Favorite

Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer

By Mukai Hirofumi   Takahashi Shunji   Nozawa Masahiro   Onozawa Yusuke   Miyazaki Jun   Ohno Keiji   Suzuki Kazuhiro  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 703-710

Springer Publishing Company

Access to resources Recommend Favorite

The role of enzalutamide in the treatment of castration-resistant prostate cancer

By Rawlinson Alex   Mohammed Aza   Miller Marek   Kunkler Roger  

Future Oncology, Vol. 8, Iss. 9, 2012-09 ,pp. : 1073-1081

Future Medicine

Access to resources Recommend Favorite

Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 10, 2009-12 ,pp. : 1040-1045

Bentham Science Publishers

Access to resources Recommend Favorite